SOPHiA GENETICS president sells 4,736 shares

SOPHiA GENETICS SA president Ross Muken reported open-market sales of ordinary shares primarily to cover taxes from equity compensation.

Rhea-AI Filing Summary

SOPHiA GENETICS SA president Ross Muken reported open-market sales of ordinary shares primarily to cover taxes from equity compensation. On April 8 and 9, 2026, he sold a total of 4,736 shares at weighted average prices of about $4.84 and $4.74 per share. The filing states these trades were executed under a pre-established Rule 10b5-1 trading plan and were made to satisfy tax withholding obligations tied to restricted stock units that vested earlier in April. After these sales, Muken still directly holds 693,361 ordinary shares, indicating the transactions represent a small portion of his overall position.

Insider Trade Summary 10b5-1

Net Seller: 4,736 shares

Net Sell 2 txns

Insider Muken Ross

Role President

Sold 4,736 shs ($23K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,950	$4.7379	$9K
Sale	Ordinary Shares	2,786	$4.8414	$13K

Holdings After Transaction: Ordinary Shares — 693,361 shares (Direct)

Footnotes (3)

1. F1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.77 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.665 to $4.85, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold April 8, 2026: 2,786 shares at $4.8414 Shares sold April 9, 2026: 1,950 shares at $4.7379 Total shares sold: 4,736 shares +3 more

6 metrics

Shares sold April 8, 2026 2,786 shares at $4.8414 Open-market sale of ordinary shares

Shares sold April 9, 2026 1,950 shares at $4.7379 Open-market sale of ordinary shares

Total shares sold 4,736 shares Combined April 8–9, 2026 transactions

Shares held after transactions 693,361 shares Direct ownership after April 9, 2026 sale

Price range April 8 trades $4.77–$4.95 Weighted average price footnote for 2,786-share sale

Price range April 9 trades $4.665–$4.85 Weighted average price footnote for 1,950-share sale

Key Terms

Rule 10b5-1 trading plan, restricted stock units, tax withholding obligations, weighted average price

4 terms

Rule 10b5-1 trading plan regulatory

"These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting"

weighted average price financial

"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SOPH president Ross Muken report in this Form 4 filing?

Ross Muken reported selling a total of 4,736 SOPHiA GENETICS ordinary shares in open-market transactions. The sales occurred on April 8 and 9, 2026, and were linked to tax withholding obligations from recently vested restricted stock units.

How many SOPH shares did Ross Muken sell and at what prices?

He sold 2,786 SOPHiA GENETICS ordinary shares at a weighted average price of $4.8414 and 1,950 shares at $4.7379. Footnotes note actual trade prices ranged from $4.77 to $4.95 and from $4.665 to $4.85, respectively.

Why did Ross Muken sell SOPHiA GENETICS (SOPH) shares in this filing?

The filing states the shares were sold to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026. These transactions are described as tax-related rather than discretionary investment decisions by the SOPHiA GENETICS president.

Were Ross Muken’s SOPH share sales made under a Rule 10b5-1 plan?

Yes. Footnotes explain the sales were executed under a pre-established Rule 10b5-1 trading plan adopted by Ross Muken. This indicates the trades were pre-planned and not timed at his discretion, reducing their informational value about his market outlook.

How many SOPHiA GENETICS shares does Ross Muken hold after these sales?

After completing these transactions, Ross Muken directly holds 693,361 SOPHiA GENETICS ordinary shares. Compared with the 4,736 shares sold for tax withholding, this shows the reported sales represent only a small portion of his overall direct ownership position.

Do these SOPH insider sales represent open-market selling by the president?

Yes, but with important context. The Form 4 classifies them as open-market sales, yet footnotes clarify they were executed solely to cover tax withholding on vested restricted stock units under a pre-established trading plan, not as discretionary portfolio moves.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/10/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Muken Ross

(Last) (First) (Middle)

C/O SOPHIA GENETICS INC.

401 PARK DRIVE, FLOOR 5

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/08/2026		S		2,786(1)	D	$4.8414(2)	695,311	D
Ordinary Shares	04/09/2026		S		1,950(1)	D	$4.7379(3)	693,361	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.77 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.665 to $4.85, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Ross Muken	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)